Filing Details
- Accession Number:
- 0001209191-23-024305
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-04-14 16:14:39
- Reporting Period:
- 2023-04-12
- Accepted Time:
- 2023-04-14 16:14:39
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1197036 | I Bruce Sachs | C/O Vertex Pharmaceuticals Incorporated 50 Northern Ave Boston MA 02210 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-04-12 | 21,300 | $72.14 | 62,510 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-04-12 | 2,917 | $325.65 | 59,593 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-04-12 | 10,357 | $326.46 | 49,236 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-04-12 | 8,026 | $327.48 | 41,210 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-04-13 | 1,210 | $0.00 | 40,000 | No | 4 | G | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | G | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-04-12 | 21,300 | $0.00 | 21,300 | $72.14 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2024-05-31 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.
- Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $325.65 (range $325.00 to $325.99).
- Open market sales reported on this line occurred at a weighted average price of $326.46 (range $326.00 to $326.97).
- Open market sales reported on this line occurred at a weighted average price of $327.48 (range $327.00 to $327.93).
- Fully vested
Billionaire Hedge Funds
